Maegim한국어

팬젠

222110KOSDAQSector: Pharma & Biotech
₩4,595▲ 0.66%Market cap ₩62.1BAs of Jul 21, 2026 close · updated once daily
A
Grade A69.8 ptsTop 12% of 2,523 stocks
Financial strength
83.3
Growth momentum
69.7
Price attractiveness
54.3

As of Jul 21, 2026 close · This grade is not a buy/sell recommendation — it is information mechanically scored from public data using a fixed formula.

1

Financial strength

83.3
How much debt does it carry relative to equity?
Debt-to-equity ratio
9.3%
✓ Above median · Top 10.8% in sector
Sector median 51.5%
Can it cover what's due within a year?
Current ratio
842.6%
✓ Above median · Top 17.7% in sector
Sector median 191.3%
How much of revenue becomes profit?
Operating margin
11.2%
✓ Above median · Top 15.8% in sector
Sector median -2.3%
How much did it earn on its own capital?
ROE (return on equity)
6.9%
✓ Above median · Top 22.6% in sector
Sector median -4.5%

Source filing: annual report (separate) — view original ↗

2

Growth momentum

69.7
How much did revenue grow in a year?
Revenue growth (YoY)
-8.6%
✗ Below median · Top 79.2% in sector
Sector median 6.4%
Has it grown steadily over three years?
Revenue 3-year CAGR
27.3%
✓ Above median · Top 9.6% in sector
Sector median 4.9%
Did core profits grow in a year?
Operating income change (YoY)
47.6%
✓ Above median · Top 20.8% in sector
Sector median 3.6%
Are core profits higher than three years ago?
Operating income change (3Y)
132.8%
✓ Above median · Top 11.6% in sector
Sector median 3.5%

Source filing: annual report (separate) — view original ↗

3

Price attractiveness

54.3
Is the price expensive relative to earnings?
P/E (price-to-earnings)
30.3x
✓ Above median · Top 31.9% in sector
Sector median P/E of profitable peers 14.4x · 57% loss-making
Is the price expensive relative to book value?
P/B (price-to-book)
2.08x
✗ Below median · Top 59.6% in sector
Sector median 1.39x

Valuation uses the Jul 21, 2026 close and market cap

Grade distribution of 248 stocks in Pharma & Biotech

S1A52B66C51D61F15